FDA clears Precision BioSciences’ IND for PBGENE-HBV to treat HBV
Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...
Physician's Weekly7h
Prognostic and Therapeutic Implications of SMARCA4 Mutations in NSCLC
The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...
European Medical Journal23h
Breakthrough Study Confirms Hepatitis E Vaccine Works in High-Risk Groups
Hepatitis E vaccine HEV 239 significantly reduces the risk of symptomatic hepatitis E among individuals with chronic ...
Precision Medicine Online37m
Precision BioSciences Nets FDA Clearance to Start Hepatitis B Gene-Editing Drug Trial
The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.